share_log

Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field

Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field

加拉帕戈斯向CellPoint下注2.25億歐元，標誌着其進入CAR-T領域
Benzinga Real-time News ·  2022/06/22 06:40
  • Galapagos (NASDAQ:GLPG) agreed to acquire CellPoint and AboundBio in an all-cash transaction propelling into next-generation cell therapy while significantly broadening its portfolio and capabilities.
  • Galapagos will pay an upfront amount of €125 million for CellPoint, an additional €100 million to be paid upon achieving certain milestones, and $14 million for AboundBio. 
  • Galapagos said that, through the acquisition of CellPoint and AboundBio, it gains access to an automated point-of-care cell therapy supply model and a next-generation fully human antibody-based therapeutics platform.
  • Related: RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value.
  • The deal aims for three next-generation CAR-Ts to the clinic over the next three years.
  • CellPoint has developed a novel point-of-care supply model, which offers the potential for efficient, 7-day delivery of CAR-T therapies and avoids complex logistics. 
  • The proprietary platform consists of CellPoint's end-to-end xCellit workflow management and monitoring software and Lonza Group's (OTC:LZAGF) Cocoon system, a closed, automated manufacturing platform for cell and gene therapies.
  • Price Action: GLPG shares are down 1.91% at $54.93 during the premarket session on the last check Wednesday.
  • 加拉帕戈斯納斯達克股票代碼：GLPG）同意以全現金交易收購CellPoint和AboundBio，推動下一代細胞療法，同時顯著擴大其產品組合和能力。
  • 加拉帕戈斯將爲CellPoint支付1.25億歐元的預付款，在實現某些里程碑後額外支付1億歐元，爲AboundBio支付1400萬美元的預付款。
  • 加拉帕戈斯表示，通過收購CellPoint和AboundBio，它獲得了自動化即時細胞療法供應模式和下一代完全基於人類抗體的治療平臺。
  • 相關： 加拿大皇家銀行預計業務發展將釋放這隻製藥股的資產負債表價值。
  • 該協議的目標是在未來三年內爲該診所提供三臺下一代CAR-T。
  • CellPoint開發了一種新穎的即時醫療供應模式，該模式有可能在7天內高效交付CAR-T療法，並避免了複雜的物流。
  • 專有平臺由CellPoint的端到端xCellit工作流程管理和監控軟件組成，以及龍沙集團的（OTC: LZAGF）Cocoon系統，一個用於細胞和基因療法的封閉式自動化製造平臺。
  • 價格走勢：在週三的最後一張支票盤前交易中，GLPG股價下跌1.91％，至54.93美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論